Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ocular Therapeutix, Inc. - Common Stock
(NQ:
OCUL
)
9.520
+0.030 (+0.32%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ocular Therapeutix, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
↗
September 30, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
September 27, 2022
Gainers
Via
Benzinga
Avidity Biosciences, Kronos Worldwide And Some Other Big Stocks Moving Lower On Tuesday
↗
September 27, 2022
U.S. stocks traded lower, with the Dow Jones dropping around 180 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Recap: Ocular Therapeutix Q2 Earnings
↗
August 08, 2022
Ocular Therapeutix (NASDAQ:OCUL) reported its Q2 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday
↗
September 30, 2022
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target.
Via
Benzinga
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
↗
September 28, 2022
Gainers
Via
Benzinga
Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
↗
September 27, 2022
Gainers
Via
Benzinga
Ocular Therapeutix's Wet AMD Candidate Shows Sustained, Comparable Clinical Activity Vs. Eylea
↗
September 27, 2022
Via
Benzinga
Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD
September 27, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
September 22, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Why Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket
↗
September 22, 2022
Gainers Spero Therapeutics, Inc. (NASDAQ: SPRO) rose 105.6% to $1.69 in pre-market trading. GSK and Spero Therapeutics announced exclusive license agreement for late-stage antibiotic asset, Tebipenem...
Via
Benzinga
Ocular Therapeutix™ to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
August 10, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update
August 08, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ To Report Second Quarter 2022 Financial Results
July 25, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Earnings Scheduled For August 8, 2022
↗
August 08, 2022
Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter.
Via
Benzinga
Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases
June 08, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ to Present at the Jefferies Healthcare Conference
June 01, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Friday
↗
May 27, 2022
During Friday's session, 59 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
↗
May 26, 2022
On Thursday, 94 companies set new 52-week lows.
Via
Benzinga
Expert Ratings for Ocular Therapeutix
↗
May 10, 2022
Over the past 3 months, 4 analysts have published their opinion on Ocular Therapeutix (NASDAQ:OCUL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding...
Via
Benzinga
Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update
May 09, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Earnings Scheduled For May 9, 2022
↗
May 09, 2022
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
Via
Benzinga
Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting
May 03, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
↗
May 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
↗
May 02, 2022
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
April 29, 2022
Gainers Ocular Therapeutix (NASDAQ:OCUL) shares moved upwards by 12.3% to $4.01 during Friday's after-market session. The company's market cap stands at $307.7 million.
Via
Benzinga
Ocular Therapeutix™ to Report First Quarter 2022 Financial Results
April 26, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ to Present Pre-Clinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 25, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Thursday
↗
April 21, 2022
On Thursday, 236 companies hit new 52-week lows.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.